𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Serum Osteoprotegerin and Receptor Activator of Nuclear Factor-κ B Ligand as Indicators of Disturbed Osteoclastogenesis in Patients With Prostate Cancer

✍ Scribed by JUNG, KLAUS; STEPHAN, CARSTEN; SEMJONOW, AXEL; LEIN, MICHAEL; SCHNORR, DIETMAR; LOENING, STEFAN A.

Book ID
121782143
Publisher
Lippincott Williams and Wilkins
Year
2003
Tongue
English
Weight
110 KB
Volume
170
Category
Article
ISSN
0022-5347

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Plasma levels of receptor activator of n
Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma
✍ Donatella Granchi; Alberto Garaventa; Ilaria Amato; Paolo Paolucci; Nicola Baldi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 141 KB

## Abstract Earlier reports showed that the balance between receptor activator of nuclear factor‐κB ligand (RANKL) and its decoy‐receptor osteoprotegerin (OPG) plays an important role in the pathogenesis of metastatic osteolysis induced by neuroblastoma cells. In this study, we investigated whether

Effects of disease-modifying antirheumat
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand
✍ Chang-Keun Lee; Eun Young Lee; Son Mi Chung; Se Hwan Mun; Bin Yoo; Hee-Bom Moon 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

## Abstract ## Objective To demonstrate the effects of disease‐modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through their effects on receptor activator of nuclear factor κB (RANK), osteoprotegerin (OPG), and RANK ligand (RANKL). ## Methods Peripheral b